研究業績

学会発表

Long-term follow-up of neoadjuvant dual anti-HER2 therapy with trastuzumab and lapatinib plus paclitaxel, with or without endocrine therapy for HER2‐positive primary breast cancer: Neo-LaTH (JBCRG-16) study.


Tomomi Fujisawa, Norikazu Masuda, Naohito Yamamoto, Hiroji Iwata, Hiroko Bando, Tomoyuki Aruga, Eriko Tokunaga, Shoichiro Ohtani, Toshimi Takano, Kenichi Inoue, Nobuyasu Suganuma, Masahiro Takada, Kenjiro Aogi, Kenichi Sakurai, Hideo Shigematsu, Katsumasa Kuroi, Hironori Haga, Shinji Ohno, Satoshi Morita, Masakazu Toi


2021.9 ESMO Poster WEB

Genomic profile and response prediction of eribulin mesylate based neoadjuvant chemotherapy in triple negative breast cancer patients


Tomomi Nishimura, Norikazu Masuda, Kosuke Kawaguchi, Masahiro Takada, Yurina Maeshima, Sunao Tanaka, Ravindranath M. Velaga, Yuichiro Kikawa, Takayuki Kadoya, Hiroko Bando, Rikiya Nakamura, Yutaka Yamamoto, Takayuki Ueno, Hiroyuki Yasojima, Hiroshi Ishiguro, Satoshi Morita, Shinji Ohno, Hironori Haga, Seishi Ogawa, Masakazu Toi


2021.9 ESMO Poster WEB

Immune microenvironment, homologous recombination deficiency and therapeutic response


Takayuki Ueno, Shigehisa Kitano, Norikazu Masuda, Daiki Ikarashi, Makiko Yamashita, Takayuki Kadoya, Hiroko Bando, Takashi Yamashita, Shoichiro Ohtani, Shigenori Nagai, Takahiro, Nakayama, Masato Takahashi, Shigehira Saji, Kenjiro Aogi, Ravindranath M. Velaga, Kosuke Kawaguchi, Satoshi Morita, Hironori Haga, Shinji Ohno, Masakazu Toi


2021.9 ESMO Poster WEB

Longitudinal alteration of cytokine profile in the peripheral blood and clinical response for neoadjuvant chemotherapy in triple-negative breast cancer patients (Translational Research of the JBCRG-22 Trial)


Kosuke Kawaguchi, Norikazu Masuda, Sunao Tanaka, Hiroko Bando, Tomomi Nishimura, Takayuki Kadoya, Takashi Yamanaka, Shigeru Imoto, Ravindranath M. Velaga, Nobuko Tamura, Tomoyuki Aruga, Yurina Maeshima, Masahiro Takada, Eiji Suzuki, Takayuki Ueno, Seishi Ogawa, Hironori Haga, Shinji Ohno, Satoshi Morita, Masakazu Toi


2021.9 ESMO Poster WEB

PRECIOUS: Pertuzumab re-treatment for HER2-positive locally advanced/metastatic breast cancer (JBCRG-M05)


Tatsuya Toyama, Yutaka Yamamoto, Hiroji Iwata, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Takashi Yamanaka, Toshimi Takano, Masahiro Kashiwaba, Norikazu Masuda, Koichiro Tsugawa, Yoshie Hasegawa, Kenji Tamura, Hiroshi Tada, Naruto Taira, Fumikata Hara, Shigehira Saji, Satoshi Morita, Masakazu Toi, Shinji Ohno


2021.3 JSMO Oral WEB

A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study


Yutaka Yamamoto, Hiroji Iwata, Taira Naruto, Norikazu Masuda, Masato Takahashi, Tetsuhiro Yoshinami, Takayuki Ueno, Tatsuya Toyama, Takashi Yamanaka, Toshimi Takano, Masahiro Kashiwaba, Koichiro Tsugawa, Yoshie Hasegawa, Kenji Tamura, Hiroshi Tada, Fumikata Hara, Shigehira Saji, Satoshi Morita, Masakazu Toi, Shinji Ohno, Japan Breast Cancer Research Group.


2020.12 SABCS Oral WEB

Influence of the adjuvant hormonal therapy on hormone sensitivity and survival outcomes in ER+ and HER2−advanced breast cancer: a subgroup analysis of the JBCRG-C06 Safari study


Takahiro Nakayama, Hidetoshi Kawaguchi, Norikazu Masuda, Shigehira Saji, Yutaka Yamamoto, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Miki Yamaguchi, Hiroko Yamashita, Toshinari Yamashita, Daisuke Yotsumoto, Satoshi Morita, Masakazu Toi, Shinji Ohno


2020年10月 第28回日本乳癌学会学術総会 ポスター WEB

A randomized, multicenter, phase II study evaluating the efficacy of interventional maintenance endocrine therapy with Bevacizumab following fixed cycles of Bevacizumab plus Paclitaxel in advanced/metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 BOOSTER trial


Shoichiro Ohtani, Shigehira Saji, Yoshie Hasegawa, Tomomi Fujisawa, Masahiro Kashiwaba, Takanori Ishida, Yutaka Yamamoto, Takashi Ishikawa, Shigenori Nagai, Hiroshi Yoshibayasi, Koji Matsumoto, Yasuaki Sagara, Masahiro Kitada, Toshimi Takano, Masahiro Takada, Norikazu Masuda, Naruto Taira, Satoshi Morita, Shinji Ohno, Masakazu Toi


2020年10月 第28回日本乳癌学会学術総会 口演 WEB

乳癌術前化学療法におけるアブラキサンの有用性についての大規模統合解析 (JBCRG-S01)


二村 学, 大庭真梨, 増田慎三, 中山貴寛, 櫻井健一, 坂東裕子, 岡田守人, 山本 豊, 金 敬徳, 佐伯俊昭, 長嶋 健 桑山隆志, 唐 宇飛, 平野 明, 井口雅史, 山神和彦, 水野 豊, 小島康幸, 八十島宏行, 大野真司


2020年10月 第28回日本乳癌学会学術総会 ポスター WEB

Outcomes of fulvestrant treatment in ER-positive HER2-positive advanced or metastatic breast cancer


Misato Masuyama, Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Koji Kaneko, Shigehira Saji, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Tomomi Fujisawa, Miki Yamaguchi, Toshinari Yamashita, Yutaka Yamamoto, Satoshi Morita, Masakazu Toi, Shinji Ohno


2020年10月 第28回日本乳癌学会学術総会 ポスター WEB

次のページへ
任意団体JBCRG 研究業績